Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Auto-generated profile, based on publicly available information
Vida Mortezaee
Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran
Diagnosing chronic pulmonary aspergillosis (CPA) is challenging due to nonspecific symptoms, variable radiological findings, and limited mycological evidences. While galactomannan (GM) testing has been validated in serum and bronchoalveolar lavage fluid (BAL) for invasive pulmonary aspergillosis (IPA), its usefulness in sputum samples for CPA remains unclear. This study aimed to determine an appropriate GM cut-off level in sputum samples and its performance in diagnosis of CPA. The diagnostic performance of sputum GM was evaluated in patients with COPD suspected of having CPA referred to the two reference centers for pulmonary diseases in Iran, and compared against established diagnostic criteria, including Aspergillus culture and IgG antibody tests. The sensitivity, specificity and positive and negative predictive value for sputum GM test were calculated. The optimal cut-off for sputum GM was determined by receiver operating characteristic (ROC). Of 196 COPD patients, 189 were analyzed for sputum GM. Sputum GM demonstrated an area under the receiver operating characteristic curve (AUC) of 0.83 (with 95 % confidence intervals (CI) of 0.748 - 0.913 and a p-value < 0.001). The optimal cut-off value for the sputum GM index was 1.44. The sensitivity and specificity were found to be 83.3 % and 74.2 % respectively. The median (IQR) levels of sputum GM index were significantly higher in CPA patients compared to non-CPA patients. (Pv <0.001). Overall, our findings suggest that sputum GM is a valuable tool in the diagnosis of CPA; however, further prospective validation is warranted to increase its clinical utility.
1 September 2021 in International Journal of Infectious Diseases
Pulmonary lymphangioleiomyomatosis (LAM) is an uncommon disease principally affecting women during childbearing years and eventually leading to progressive respiratory failure. Lung transplantation is a viable option for patients with end-stage disease. LAM-related complications remain common, but recurrence of LAM following allograft transplantation is rare. We present a 25-year-old woman who presented with progressive dyspnea five years after bilateral lung transplantation for end-stage LAM. Histological examination of transbronchial lung biopsy sample confirmed recurrent LAM. We changed cyclosporine to sirolimus and she is currently being considered for re-transplantation.